Patients with histologically proven urothelial carcinoma whose tumors were FGFR-3 positive and who had received at least one course of platinum-based chemotherapy in the past and whose disease had progressed were enrolled in the phase Ib/II study showing efficiency of vofatamab with or without docetaxel (FIERCE-21) [73]. This evidence concerns the gene FGFR3 and urothelial carcinoma.